Physician profile
John Andrefsky
NPI 1356373344
$147,289.45
in general payments reported to CMS, 2019-2025
67 companies · $3,441 in 2025
The $3,441 reported for 2025 was more than what 85% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,051 · 2020: $35K · 2021: $39K · 2022: $22K · 2023: $37K · 2024: $9,284 · 2025: $3,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $13K · Food and Beverage: $8,923 · Travel and Lodging: $1,580 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,562.00 |
| Consulting Fee | $13,323.00 |
| Food and Beverage | $8,923.18 |
| Travel and Lodging | $1,580.23 |
| Education | $201.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55,921.31 | 2021-2025 | Ubrelvy, Qulipta, Duopa |
| Harmony Biosciences LLC | $34,405.80 | 2020-2025 | Wakix |
| Allergan, INC. | $29,954.59 | 2020-2021 | |
| Axsome Therapeutics, INC. | $13,745.03 | 2022-2025 | Sunosi, Symbravo |
| Noctrix Health, INC. | $1,451.91 | 2025 | Nidra |
| Genentech USA, INC. | $1,198.33 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Jazz Pharmaceuticals INC. | $1,039.39 | 2019-2025 | |
| Lilly USA, LLC | $1,023.89 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Sk Life Science, INC. | $956.23 | 2020-2025 | Xcopri |
| Pfizer INC. | $585.39 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $500.78 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $480.99 | 2019-2024 | Austedo, Austedo Xr, Ajovy |
| Lundbeck LLC | $377.81 | 2019-2025 | Vyepti, Rexulti |
| Ucb, INC. | $363.73 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Biogen, INC. | $345.67 | 2019-2024 | Vumerity, Tysabri |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Andrefsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.